KBC Group’s Vanda Pharmaceuticals VNDA Stock Holding History

KBC Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,142	Closed	-$21K	–	1949
2023 Q2	$21K	Hold	3,142	–	–	﹤0.01%	1467
2023 Q1	$21K	Sell	3,142 -2,341	-43%	-$16.5K	﹤0.01%	1489
2022 Q4	$41K	Hold	5,483	–	–	﹤0.01%	1436
2022 Q3	$54K	Hold	5,483	–	–	﹤0.01%	1376
2022 Q2	$60K	Sell	5,483 -5,389	-50%	-$55.8K	﹤0.01%	1385
2022 Q1	$123K	Sell	10,872 -10,188	-48%	-$134K	﹤0.01%	1132
2021 Q4	$330K	Hold	21,060	–	–	﹤0.01%	968
2021 Q3	$361K	Sell	21,060 -21,060	-50%	-$369K	﹤0.01%	952
2021 Q2	$906K	Hold	42,120	–	–	﹤0.01%	903
2021 Q1	$632K	Buy	42,120 +26,668	+173%	+$432K	﹤0.01%	993
2020 Q4	$1.12M	Hold	15,452	–	–	﹤0.01%	1132
2020 Q3	$150K	Hold	15,452	–	–	﹤0.01%	1150
2020 Q2	$176K	Buy	+15,452	New	+$175K	﹤0.01%	1168

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KBC Group's VNDA Position: Q3 2023 in Review

KBC Group sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 3,142 shares — an estimated $21K sold.

KBC Group first reported a position in VNDA in Q2 2020 and held it in 13 quarters. The position peaked at $1.12M in Q4 2020. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

KBC Group reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
KBC Group sold 3,142 Vanda Pharmaceuticals shares in Q3 2023, an estimated $21K.
KBC Group first reported a position in Vanda Pharmaceuticals in Q2 2020 and held it in 13 quarters.
KBC Group's Vanda Pharmaceuticals position peaked at $1.12M in Q4 2020.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on KBC Group's 13F filing for Q3 2023, filed 22 Nov 2023.